gutsandgrowth

Home | About Jay Hochman -Pediatric Gastroenterology Blog | Archives

Polyethylene Glycol in the First Two Years of Life

May 20, 2021 7:00 am

A recent retrospective study (D Roy et al. JPGN 2021; 72: 683-689. Full text: Utilisation and Safety of Polyethylene Glycol 3350 With Electrolytes in Children Under 2 Years) provides some reassurance that use of polyethylene glycol 3350 (PEG) (aka Miralax) was well-tolerated in children <2 years of age.

From an initial cohort of 20,861 from the Clinical Practice Research Datalink (CPRD) GOLD, the authors identified 13,235 patients with a constipation indication and 40 patients with fecal impaction indication for PEG.

Key finding:

The safety aspect of this study did not identify any signals of concern in the constipation cohort.
The mean duration of exposure, in the first treatment episode, was 88.9 days.
9380 patients (70.9%) were aged between 12 and <24 months, with a further 3855 patients (29.1%) aged <12months. Also, PEG 3350+E was used in 477 patients (3.6%) who were <6 months of age

This type of retrospective study is less capable of detecting adverse events than a prospective study and is limited by how carefully the primary care provider elicits and documents them.

My take: This large study confirms the widespread usage of PEG in young children without apparent adverse reactions.

Related blog posts: